A phase II trial of a non-myeloablative regimen combining in vivo T cell depletion with an anti-CD52 monoclonal antibody (alemtuzumab), and chemotherapy with fludarabine and melphalan prior to a related or unrelated hematopoietic stem cell transplantation Meeting Abstract

  

Authors:	Castro-Malaspina, H.; Papadopoulos, E.; Jakubowski, A.; Perales, M. A.; Young, J.; Hsu, K.; Boulad, F.; Prasad, V.; Small, T.; Kernan, N.; Van Den Brink, M.; Dastigir, H.; O'reilly, R.
Abstract Title:	A phase II trial of a non-myeloablative regimen combining in vivo T cell depletion with an anti-CD52 monoclonal antibody (alemtuzumab), and chemotherapy with fludarabine and melphalan prior to a related or unrelated hematopoietic stem cell transplantation
Meeting Title:	2004 Tandem BMT Meetings
Journal Title:	Biology of Blood and Marrow Transplantation
Volume:	10
Issue:	Suppl. 1
Meeting Dates:	2004 Feb 13-17
Meeting Location:	Orlando, FL
ISSN:	1083-8791
Publisher:	Elsevier Inc.
Date Published:	2004-02-01
Start Page:	40
Language:	English
ACCESSION:	WOS:000188877500094
DOI:	10.1016/j.bbmt.2003.12.188
PROVIDER:	wos
Notes:	Meeting Abstract: 92 -- Poster session I -- Tandem BMT 2004 Meeting -- FEB 13-17, 2004 -- ORLANDO, FLORIDA -- 1 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/57362